Professor Karla Zadnik, Dean of the Ohio State University College of Optometry in the USA,, discusses the Childhood Atropine for Myopia Progression (CHAMP) study, engaging with the literature, her favourite papers and an alternative take on myopia control as standard of care.
The research information on using atropine for myopia control is evolving. Previous research indicated 0.01% atropine was best, but newer research says otherwise. In this clinical case, practitioners discuss treatment strategies, which are put in research context with clinical pearls for practice.
A child has an allergic reaction to low dose atropine – or does he? Here practitioners consider the possible causes, with advice for management. We then frame this discussion in view of the evidence-base with take home clinical messages.
Atropine can be used for myopia control as a monotherapy or as an adjunct to an optical intervention – we discuss patient selection, atropine combination treatments, how to taper and when to stop.
Most atropine currently prescribed for myopia control is compounded. How could this influence consistency of treatment and research results? What could current research lead to in future prescribing? Read more here.
A two-year-old with high myopia and astigmatism – the discussion included co-management, the best optical correction, and the lifelong management ahead. Read more on managing the myopic toddler.
MCS was hesitating fitting OrthoK to a patient who showed inferior corneal steepening. Her main concern was that OrthoK may
There’s a common clinical belief that Orthokeratology (OK) doesn’t work as well in lower myopes for myopia control. I’ve even
When it comes to myopic teenagers and stabilization of their myopia progression, we have some research data available. Studies such
So you have initiated myopia treatment and had a successful control of a rapid progressor’s myopia. When should you stop
